The FDA has granted fast-track designation to an investigational small molecule to treat individuals with Fragile X syndrome, ...
There are currently no FDA-approved treatments for FXS, a disease that affects approximately 1 in 4-5000 men and 1 in 6-8000 women globally.
L’incidenza è stabile nelle fasce di età pediatrica, mentre è in aumento nei giovani adulti e negli anziani. Più colpiti i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback